Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2021

01-05-2021 | Stroke

Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data

Authors: Wern Yew Ding, Gregory Y. H. Lip, Stefano Bartoletti, Lindsay Morrison, Afshin Khalatbari, Suneil Aggarwal, Periaswamy Velavan, Dhiraj Gupta

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2021

Login to get access

Abstract

Long-term follow-up data of left atrial appendage (LAA) occlusion in patients with atrial fibrillation (AF) are sparse. To address these data gaps, we analysed the 4-year outcomes of AF patients following LAA occlusion. The was a retrospective cohort study of high-risk patients with AF who underwent successful implantation of the Amulet device at our center between 2014 and 2017. Study endpoints were the rate of stroke, major bleeding and all-cause mortality. We included 71 patients (35.2% females) with a median age of 78 (IQR 73–82) years. Over a median follow-up period of 46 (IQR 19–56) months, the annual rate of ischemic stroke was 1.06 events/100 patient-years (95% CI 0–2.35), hemorrhagic stroke was 1.06 events/100 patient-years (95% CI 0–2.35) and major extracranial bleeding that required unplanned hospital admission was 1.84 events/100 patient-years (95% CI 0.25–3.43). A total of 28 (39.4%) patients died during this period with an annual mortality rate of 10.29 events/100 patient-years (95% CI 7.25–13.32). Our experience suggests that LAA occlusion using the Amulet device appears to be associated with a low risk of ischemic stroke in high-risk AF patients who are deemed unsuitable for oral anticoagulation; however, these patients have a high rate of mortality over the medium to long-term follow-up, and an ongoing significant risk of bleeding and thrombotic events.
Literature
Metadata
Title
Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data
Authors
Wern Yew Ding
Gregory Y. H. Lip
Stefano Bartoletti
Lindsay Morrison
Afshin Khalatbari
Suneil Aggarwal
Periaswamy Velavan
Dhiraj Gupta
Publication date
01-05-2021
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02333-y

Other articles of this Issue 4/2021

Journal of Thrombosis and Thrombolysis 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine